Dan Moore, PhD
Email: MooreDX@cpmcri.org
Introduction
I'm a biostatistician who enjoys working on a wide variety of medical studies, including breast cancer, bladder cancer, colon cancer and leukemia. I am responsible for the design and analysis of data from clinical trials of treatments for ALS (Lou Gehrig's Disease).
I am currently interested in developing statistical and graphical methods for understanding the relationship between genetics and cancer through the use of microchip arrays. I am also interested in methods of risk adjustment and measuring healthcare outcomes.
I have been at the research institute since 1994, after retiring from the Lawrence Livermore National Laboratory, where I worked for 21 years.
Back to top
Publications
Click to see List of publications by Dan Moore, Ph.D. in affiliation with CPMCRI in PubMed.
Representative publications include:
Moore DH 2nd. Pallavicini M. Cher ML. Gray JW. A t-statistic for objective interpretation of comparative genomic hybridization (CGH) profiles. Cytometry 28(3):183-90, 1997
Moore DH 2nd. Tucker JD. Jones IM. Langlois RG. Pleshanov P. Vorobtsova I. Jensen R. A study of the effects of exposure on cleanup workers at the Chernobyl nuclear reactor accident using multiple end points. Radiation Research 148(5):463-75, 1997
Goodson WH 3rd. Moore DH 2nd. Ljung BM. Chew K. Florendo C. Mayall B. Smith HS. Waldman FM. The functional relationship between in vivo bromodeoxyuridine labeling index and Ki-67 proliferation index in human breast cancer. Breast Cancer Research & Treatment 49(2):155-64, 1998
Chen LC. Manjeshwar S. Lu Y. Moore D. Ljung BM. Kuo WL. Dairkee SH. Wernick M. Collins C. Smith HS. The human homologue for the Caenorhabditis elegans cul-4 gene is amplified and overexpressed in primary breast cancers. Cancer Research 58(16):3677-83, 1998
Sicher F. Targ E. Moore D 2nd. Smith HS. A randomized double-blind study of the effect of distant healing in a population with advanced AIDS. Report of a small scale study. Western Journal of Medicine 169(6):356-63, 1998.
Back to top
